Jongo S et al., 2026: Phase 1 randomized placebo-controlled trial of an oxfendazole tablet in 30 healthy African volunteers, giving 100 mg or 400 mg single doses or 400 mg daily for five days. Median half-life was 11.6-13.9 h and no adverse events were reported.
The median elimination half-life ranged from 11.6 to 13.9 h and was consistent across cohorts.
Jongo S et al., 2026: Phase 1 randomized placebo-controlled trial of an oxfendazole tablet in 30 healthy African volunteers, giving 100 mg or 400 mg single doses or 400 mg daily for five days. Median half-life was 11.6-13.9 h and no adverse events were reported. Phase 1, randomized, placebo-controlled bioavailability trial; N=30 healthy adults, randomized 8:2 oxfendazole:placebo per cohort; Tanzania (Bagamoyo); oxfendazole 100 mg or 400 mg single dose, or 400 mg daily for 5 days, immediate-release tablet; NCT04920292. Funder: Horizon 2020 grant 815628. Declared conflicts: authors declare no conflict of interest. Product: oxfendazole tablet, formulation developed by the trial consortium. Comparator: placebo. Human oxfendazole data, not fenbendazole; it is the most recent human PK for the metabolite. Study type: randomized trial.
